Nanoways to overcome docetaxel resistance in prostate cancer

Drug Resistance Updates

Volumn 17, Issue 1-2, 2014, Pages 13-23

  Ganju, Aditya ^a   Yallapu, Murali M ^a   Khan, Sheema ^a   Behrman, Stephen W ^a   Chauhan, Subhash C ^a   Jaggi, Meena ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Chemoresistance; Docetaxel; Drug delivery; Drug targeting; Nanomedicine; Nanoparticles; Nanotechnology; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG CARRIER; MICRORNA; MIRN205 MICRORNA, HUMAN; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; TAXOID;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84902546498     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.04.001     Document Type: Review

References (115)

1. A. Ahmed, S. Ali, and F.H. Sarkar Advances in androgen receptor targeted therapy for prostate cancer J. Cell. Physiol. 229 2014 271 276
2. S. Al Ekish, M. Nayeemuddin, M. Maddox, and G. Pareek The role of cryosurgery of the prostate for nonsurgical candidates JSLS: J. Soc. Laparoendosc. Surg./Soc. Laparoendosc. Surg. 17 2013 423 428
3. A.M. Aparicio, A.L. Harzstark, P.G. Corn, S. Wen, J.C. Araujo, S.M. Tu, L.C. Pagliaro, J. Kim, R.E. Millikan, C. Ryan, N.M. Tannir, A.J. Zurita, P. Mathew, W. Arap, P. Troncoso, P.F. Thall, and C.J. Logothetis Platinum-based chemotherapy for variant castrate-resistant prostate cancer Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 19 2013 3621 3630
4. R.R. Arvizo, S. Bhattacharyya, R.A. Kudgus, K. Giri, R. Bhattacharya, and P. Mukherjee Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future Chem. Soc. Rev. 41 2012 2943 2970
5. R.R. Arvizo, O.R. Miranda, D.F. Moyano, C.A. Walden, K. Giri, R. Bhattacharya, J.D. Robertson, V.M. Rotello, J.M. Reid, and P. Mukherjee Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles PLoS ONE 6 2011 pe24374
6. A. Bahl, S. Masson, A. Birtle, S. Chowdhury, and J. de Bono Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents Cancer Treat. Rev. 40 2014 170 177
7. N. Bhatnagar, X. Li, S.K. Padi, Q. Zhang, M.S. Tang, and B. Guo Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells Cell Death Dis. 1 2010 pe105
8. S. Bhattacharyya, J.A. Khan, G.L. Curran, J.D. Robertson, R. Bhattacharya, and P. Mukherjee Efficient delivery of gold nanoparticles by dual receptor targeting Adv. Mater. 23 2011 5034 5038
9. K.S. Chu, A.N. Schorzman, M.C. Finniss, C.J. Bowerman, L. Peng, J.C. Luft, A.J. Madden, A.Z. Wang, W.C. Zamboni, and J.M. DeSimone Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy Biomaterials 34 2013 8424 8429
10. S.J. Clarke, and L.P. Rivory Clinical pharmacokinetics of docetaxel Clin. Pharmacokinet. 36 1999 99 114
11. V. Coppola, R. De Maria, and D. Bonci MicroRNAs and prostate cancer Endocr. Relat. Cancer 17 2010 F1 F17
12. M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Escuin, X.K. Zhou, A. Gjyrezi, C. Chanel-Vos, R. Shen, S.T. Tagawa, N.H. Bander, D.M. Nanus, and P. Giannakakou Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res. 71 2011 6019 6029
13. R. de Oliveira, P. Zhao, N. Li, L.C. de Santa Maria, J. Vergnaud, J. Ruiz, D. Astruc, and G. Barratt Synthesis and in vitro studies of gold nanoparticles loaded with docetaxel Int. J. Pharm. 454 2013 703 711
14. J.F. Deeken, R. Slack, G.J. Weiss, R.K. Ramanathan, M.J. Pishvaian, J. Hwang, K. Lewandowski, D. Subramaniam, A.R. He, I. Cotarla, A. Rahman, and J.L. Marshall A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies Cancer Chemother. Pharmacol. 71 2013 627 633
15. H. Devalapally, D. Shenoy, S. Little, R. Langer, and M. Amiji Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model Cancer Chemother. Pharmacol. 59 2007 477 484
16. E.V. Diane Lauren Reidy, M.G. Fakih, Muhammad Wasif Saif, J. Randolph Hecht, N. Goodman-Davis, E. Hollywood, J. Shia, J. Schwartz, K. Chandrawansa, A. Dontabhaktuni, H. Youssoufian, D.B. Solit, and L.B. Saltz Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J. Clin. Oncol. 28 2010 4240 4246
17. R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani, and F. Atyabi Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomed. 6 2011 877 895
18. A.M. El-Toni, M.A. Ibrahim, J.P. Labis, A. Khan, and M. Alhoshan Optimization of synthesis parameters for mesoporous shell formation on magnetic nanocores and their application as nanocarriers for docetaxel cancer drug Int. J. Mol. Sci. 14 2013 11496 11509
19. R.L. Elliott Combination cancer immunotherapy "expanding paul ehrlich's magic bullet concept" Surg. Oncol. 21 2012 53 55
20. E.M. Enlow, J.C. Luft, M.E. Napier, and J.M. DeSimone Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings Nano Lett. 11 2011 808 813
21. F. Esmaeili, R. Dinarvand, M.H. Ghahremani, M. Amini, H. Rouhani, N. Sepehri, S.N. Ostad, and F. Atyabi Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies J. Pharm. Sci. 98 2009 2718 2730
22. L. Feng, H. Wu, P. Ma, R.J. Mumper, and S.R. Benhabbour Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo Int. J. Nanomed. 6 2011 2545 2556
23. O. Fernandez, J. Afonso, S. Vazquez, B. Campos, M. Lazaro, L. Leon, and L.M. Anton Aparicio Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel Anti-Cancer Drugs 25 2014 37 43
24. K. Fizazi, J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, N.B. Davis, M. Qi, R. Bandekar, J.T. Vermeulen, M. Cornfeld, and G.R. Hudes Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur. J. Cancer (Oxf. Engl.: 1990) 48 2012 85 93
25. S. Gale, and G. Croasdell 28th Annual JPMorgan Healthcare Conference - Exelixis and Nektar Therapeutics IDrugs: Investig. Drugs J. 13 2010 139 141
26. P. Gandellini, M. Folini, N. Longoni, M. Pennati, M. Binda, M. Colecchia, R. Salvioni, R. Supino, R. Moretti, P. Limonta, R. Valdagni, M.G. Daidone, and N. Zaffaroni miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon Cancer Res. 69 2009 2287 2295
27. P. Gandellini, M. Folini, and N. Zaffaroni Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol. Med. 15 2009 381 390
28. P. Gandellini, V. Profumo, A. Casamichele, N. Fenderico, S. Borrelli, G. Petrovich, G. Santilli, M. Callari, M. Colecchia, S. Pozzi, M. De Cesare, M. Folini, R. Valdagni, R. Mantovani, and N. Zaffaroni miR-205 regulates basement membrane deposition in human prostate: implications for cancer development Cell Death Differ. 19 2012 1750 1760
29. P. Giannakakou, R. Gussio, E. Nogales, K.H. Downing, D. Zaharevitz, B. Bollbuck, G. Poy, D. Sackett, K.C. Nicolaou, and T. Fojo A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc. Natl. Acad. Sci. U. S. A. 97 2000 2904 2909
30. A.A. Goldberg, V.I. Titorenko, A. Beach, and J.T. Sanderson Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells PeerJ 1 2013 pe122
31. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
32. D.S. Grant, T.L. Williams, M. Zahaczewsky, and A.P. Dicker Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int. J. Cancer J. Int. Du Cancer 104 2003 121 129
33. K. Hadinoto, A. Sundaresan, and W.S. Cheow Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V. 2013
34. C.S. Higano Potential use of custirsen to treat prostate cancer OncoTargets Ther. 6 2013 785 797
35. K.S. Ho, A.M. Aman, R.S. Al-awar, and M.S. Shoichet Amphiphilic micelles of poly(2-methyl-2-carboxytrimethylene carbonate-co-d,l-lactide)-graft- poly(ethylene glycol) for anti-cancer drug delivery to solid tumours Biomaterials 33 2012 2223 2229
36. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128ra139
37. C.M. Hu, and L. Zhang Therapeutic nanoparticles to combat cancer drug resistance Curr. Drug Metab. 10 2009 836 841
38. J. Johnson, and M.3rd Roach Prostate cancer: impact of national guidelines on brachytherapy monotherapy Nat. Rev. Urol. 11 2014 195 196
39. S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, and P.M. Ravdin Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 23 2005 5542 5551
40. Z. Khatun, M. Nurunnabi, G.R. Reeck, K.J. Cho, and Y.K. Lee Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy J. Control. Release: Off. J. Control. Release Soc. 170 2013 74 82
41. J. Kim, L. Wu, J.C. Zhao, H.J. Jin, and J. Yu TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c Oncogene 2013 10.1038/onc.2013.461
42. D. Kobayashi, N. Kawai, S. Sato, T. Naiki, K. Yamada, T. Yasui, K. Tozawa, T. Kobayashi, S. Takahashi, and K. Kohri Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model Prostate 73 2013 913 922
43. K. Komura, T. Inamoto, T. Takai, T. Uchimoto, K. Saito, N. Tanda, J. Kono, K. Minami, H. Uehara, Y. Fujisue, K. Takahara, H. Hirano, H. Nomi, T. Watsuji, S. Kiyama, and H. Azuma Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy World J. Urol. 2013 10.1007/s00345-013-1215-z
44. F. Kopp, P.S. Oak, E. Wagner, and A. Roidl miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression PLOS ONE 7 2012 pe50469
45. C.M. Kruijtzer, J.H. Beijnen, and J.H. Schellens Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview Oncologist 7 2002 516 530
46. S.W. Lee, M.H. Yun, S.W. Jeong, C.H. In, J.Y. Kim, M.H. Seo, C.M. Pai, and S.O. Kim Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system J. Control. Release: Off. J. Control. Release Soc. 155 2011 262 271
47. X. Li, X. Tian, J. Zhang, X. Zhao, X. Chen, Y. Jiang, D. Wang, and W. Pan In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel Int. J. Nanomed. 6 2011 1167 1184
48. Y. Li, F. Yang, W. Chen, J. Liu, W. Huang, M. Jin, and Z. Gao A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study Chem. Pharm. Bull. 60 2012 1146 1154
49. B. Liu, M. Yang, R. Li, Y. Ding, X. Qian, L. Yu, and X. Jiang The antitumor effect of novel docetaxel-loaded thermosensitive micelles Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V. 69 2008 527 534
50. Q. Liu, R.T. Li, H.Q. Qian, J. Wei, L. Xie, J. Shen, M. Yang, X.P. Qian, L.X. Yu, X.Q. Jiang, and B.R. Liu Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles Biomaterials 34 2013 7191 7203
51. Z. Liu, Y. Wang, J. Zhang, M. Li, Y. Liu, and N. Zhang Pluronic P123-docetaxel conjugate micelles: synthesis, characterization, and antitumor activity J. Biomed. Nanotechnol. 9 2013 2007 2016
52. M. Ma, Y. Hao, N. Liu, Z. Yin, L. Wang, X. Liang, and X. Zhang A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution Int. J. Nanomed. 7 2012 3389 3398
53. S.K. Manna, S. Sarkar, J. Barr, K. Wise, E.V. Barrera, O. Jejelowo, A.C. Rice-Ficht, and G.T. Ramesh Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-kappaB in human keratinocytes Nano Lett. 5 2005 1676 1684
54. S. Manoocheheri, B. Darvishi, G. Kamalinia, M. Amini, M. Fallah, S.N. Ostad, F. Atyabi, and R. Dinarvand Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel DARU: J. Fac. Pharm. Tehran Univ. Med. Sci. 21 2013 p58
55. ® PLOS ONE 8 2013 pe62630
56. M. Mimeault, S.L. Johansson, and S.K. Batra Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies PLOS ONE 7 2012 pe31919
57. K.H. Min, H.J. Lee, K. Kim, I.C. Kwon, S.Y. Jeong, and S.C. Lee The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles Biomaterials 33 2012 5788 5797
58. N. Mody, R.K. Tekade, N.K. Mehra, P. Chopdey, and N.K. Jain Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential AAPS PharmSciTech 15 2014 388 399
59. ®) Tetrahed. Lett. 35 1994 3715 3718
60. M.S. Muthu, S.A. Kulkarni, A. Raju, and S.S. Feng Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots Biomaterials 33 2012 3494 3501
61. K.L. Nair, S. Jagadeeshan, S.A. Nair, and G.S. Kumar Evaluation of triblock copolymeric micelles of delta-valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer J. Nanobiotechnol. 9 2011 p42
62. 13C]pyruvate Sci. Transl. Med. 5 2013 198ra108
63. J.H. Nettles, H. Li, B. Cornett, J.M. Krahn, J.P. Snyder, and K.H. Downing The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography Science 305 2004 866 869
64. A.J. O'Neill, M. Prencipe, C. Dowling, Y. Fan, L. Mulrane, W.M. Gallagher, D. O'Connor, R. O'Connor, A. Devery, C. Corcoran, S. Rani, L. O'Driscoll, J.M. Fitzpatrick, and R.W. Watson Characterisation and manipulation of docetaxel resistant prostate cancer cell lines Mol. Cancer 10 2011 p126
65. K.L. Penney, M.J. Stampfer, J.L. Jahn, J.A. Sinnott, R. Flavin, J.R. Rider, S. Finn, E. Giovannucci, H.D. Sesso, M. Loda, L.A. Mucci, and M. Fiorentino Gleason grade progression is uncommon Cancer Res. 73 2013 5163 5168
66. K.P. Porkka, M.J. Pfeiffer, K.K. Waltering, R.L. Vessella, T.L. Tammela, and T. Visakorpi MicroRNA expression profiling in prostate cancer Cancer Res. 67 2007 6130 6135
67. G. Qu, X. Wu, L. Yin, and C. Zhang N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics Biomed. Pharmacother. Biomed. Pharmacother. 66 2012 46 51
68. A. Raju, M.S. Muthu, and S.S. Feng Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel Expert Opin. Drug Deliv. 10 2013 747 760
69. I. Royer, B. Monsarrat, M. Sonnier, M. Wright, and T. Cresteil Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs Cancer Res. 56 1996 58 65
70. F. Saad, S. Hotte, S. North, B. Eigl, K. Chi, P. Czaykowski, L. Wood, M. Pollak, S. Berry, J.B. Lattouf, S.D. Mukherjee, M. Gleave, and E. Winquist Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c Clinical Cancer Res.: Off. J. Am. Assoc. Cancer Res. 17 2011 5765 5773
71. 4 enhance docetaxel-induced prostate cancer cell death Int. J. Nanomed. 8 2013 3151 3160
72. A. Schaefer, C. Stephan, J. Busch, G.M. Yousef, and K. Jung Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors Nat. Rev. Urol. 7 2010 286 297
73. J. Shen, Q. He, Y. Gao, J. Shi, and Y. Li Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism Nanoscale 3 2011 4314 4322
74. D. Shenoy, S. Little, R. Langer, and M. Amiji Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations Mol. Pharm. 2 2005 357 366
75. K. Shimoda, and N. Kubota Chemo-enzymatic synthesis of ester-linked docetaxel-monosaccharide conjugates as water-soluble prodrugs Molecules 16 2011 6769 6777
76. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics 2013 CA: Cancer J. Clin. 63 2013 11 30
77. G. Song, C. Lee, D. You, I.G. Jeong, J.H. Hong, H. Ahn, and C.S. Kim Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice Prostate Int. 1 2013 125 132
78. S. Sorensen, L. Ellis, Y. Wu, V. Hutchins, J.E. Linnehan, and M. Senbetta Budgetary impact on a U.S. Health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer J. Managed Care Pharm.: JMCP 19 2013 799 808
79. A. Sosnik Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: a review Adv. Drug Deliv. Rev. 65 2013 1828 1851
80. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat. Rev. Cancer 8 2008 473 480
81. S. Svenson What nanomedicine in the clinic right now really forms nanoparticles? Wiley Interdiscipl. Rev.: Nanomed. Nanobiotechnol. 6 2014 125 135
82. Q. Tan, X. Liu, X. Fu, Q. Li, J. Dou, and G. Zhai Current development in nanoformulations of docetaxel Expert Opin. Drug Deliv. 9 2012 975 990
83. W. Tao, X. Zeng, T. Liu, Z. Wang, Q. Xiong, C. Ouyang, L. Huang, and L. Mei Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy Acta Biomater. 9 2013 8910 8920
84. A.L. Teixeira, M. Gomes, A. Nogueira, A.S. Azevedo, J. Assis, F. Dias, J.I. Santos, F. Lobo, A. Morais, J. Mauricio, and R. Medeiros Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in tgfbeta1 signaling pathway modulation PLOS ONE 8 2013 pe72419
85. R. Tong, and J. Cheng Drug-initiated, controlled ring-opening polymerization for the synthesis of polymer-drug conjugates Macromolecules 45 2012 2225 2232
86. R. Tong, H.H. Chiang, and D.S. Kohane Photoswitchable nanoparticles for in vivo cancer chemotherapy Proc. Natl. Acad. Sci. U. S. A. 110 2013 19048 19053
87. S.W. Tong, B. Xiang, D.W. Dong, and X.R. Qi Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles Int. J. Pharm. 434 2012 413 419
88. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, and C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
89. K. Ueda, C. Cardarelli, M.M. Gottesman, and I. Pastan Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine Proc. Natl. Acad. Sci. U. S. A. 84 1987 3004 3008
90. R. van der Meel, L.J. Vehmeijer, R.J. Kok, G. Storm, and E.V. van Gaal Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status Adv. Drug Deliv. Rev. 65 2013 1284 1298
91. J. Verweij, M. Clavel, and B. Chevalier Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 5 1994 495 505
92. D. Wang, J. Huang, X. Wang, Y. Yu, H. Zhang, Y. Chen, J. Liu, Z. Sun, H. Zou, D. Sun, G. Zhou, G. Zhang, Y. Lu, and Y. Zhong The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel Biomaterials 34 2013 7662 7673
93. L. Wang, M. Zhang, N. Zhang, J. Shi, H. Zhang, M. Li, C. Lu, and Z. Zhang Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes Int. J. Nanomed. 6 2011 2641 2652
94. A. Watahiki, R.J. Macfarlane, M.E. Gleave, F. Crea, Y. Wang, C.D. Helgason, and K.N. Chi Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer Int. J. Mol. Sci. 14 2013 7757 7770
95. B.S. Wong, S.L. Yoong, A. Jagusiak, T. Panczyk, H.K. Ho, W.H. Ang, and G. Pastorin Carbon nanotubes for delivery of small molecule drugs Adv. Drug Deliv. Rev. 65 2013 1964 2015
96. M.M. Yallapu, M.R. Dobberpuhl, D.M. Maher, M. Jaggi, and S.C. Chauhan Design of curcumin loaded cellulose nanoparticles for prostate cancer Curr. Drug Metab. 13 2012 120 128
97. M.M. Yallapu, M.C. Ebeling, M. Jaggi, and S.C. Chauhan Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics Curr. Drug Metab. 14 2013 504 515
98. M.M. Yallapu, M.C. Ebeling, S. Khan, V. Sundram, N. Chauhan, B.K. Gupta, S.E. Puumala, M. Jaggi, and S.C. Chauhan Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment Mol. Cancer Therap. 12 2013 1471 1480
99. M.M. Yallapu, S.P. Foy, T.K. Jain, and V. Labhasetwar PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications Pharmaceut. Res. 27 2010 2283 2295
100. M.M. Yallapu, B.K. Gupta, M. Jaggi, and S.C. Chauhan Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells J. Colloid Interface Sci. 351 2010 19 29
101. M.M. Yallapu, M. Jaggi, and S.C. Chauhan Scope of nanotechnology in ovarian cancer therapeutics J. Ovarian Res. 3 2010 p19
102. M.M. Yallapu, S.F. Othman, E.T. Curtis, N.A. Bauer, N. Chauhan, D. Kumar, M. Jaggi, and S.C. Chauhan Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications Int. J. Nanomed. 7 2012 1761 1779
103. M.M. Yallapu, S.F. Othman, E.T. Curtis, B.K. Gupta, M. Jaggi, and S.C. Chauhan Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy Biomaterials 32 2011 1890 1905
104. Y. Yamamoto, M. Yoshida, M. Sato, K. Sato, S. Kikuchi, H. Sugishita, J. Kuwabara, Y. Matsuno, Y. Kojima, M. Morimoto, A. Horiuchi, and Y. Watanabe Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts Int. J. Oncol. 38 2011 33 39
105. M. Yazdi, Z.N. Najafi, M. Khorramizadeh, M. Amini, and A. Shahverdi Fabrication of docetaxel surfaced Fe3O4 magnetite nanoparticles and their cytotoxicity on 4 T1 breast cancer cells DARU: J. Fac. Pharm. Tehran Univ. Med. Sci. 20 2012 p15
106. M. Yoshida, M. Sato, Y. Yamamoto, T. Maehara, T. Naohara, H. Aono, H. Sugishita, K. Sato, and Y. Watanabe Tumor local chemohyperthermia using docetaxel-embedded magnetoliposomes: Interaction of chemotherapy and hyperthermia J. Gastroenterol. Hepatol. 27 2012 406 411
107. Y. Yu, Y. He, B. Xu, Z. He, Y. Zhang, Y. Chen, Y. Yang, Y. Xie, Y. Zheng, G. He, J. He, and X. Song Self-assembled methoxy poly(ethylene glycol)-cholesterol micelles for hydrophobic drug delivery J. Pharm. Sci. 102 2013 1054 1062
108. Z. Yuan, D. Chen, S. Zhang, and Z. Zheng Preparation, characterization and evaluation of docetaxel-loaded, folate-conjugated PEG-liposomes Yakugaku Zasshi: J. Pharm. Soc. Japan 130 2010 1353 1359
109. H. Zhang, R.Y. Li, X. Lu, Z.Z. Mou, and G.M. Lin Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution J. Zhejiang Univ. Sci. B 13 2012 981 989
110. W. Zhang, D. Zhang, J. Tan, and H. Cong Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel J. Nanosci. Nanotechnol. 12 2012 7211 7214
111. J. Zhao, Y. Mi, and S.S. Feng Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles Biomaterials 34 2013 3411 3421
112. S. Zhao, S. Tan, Y. Guo, J. Huang, M. Chu, H. Liu, and Z. Zhang pH-sensitive docetaxel-loaded d-alpha-tocopheryl polyethylene glycol succinate-poly(beta-amino ester) copolymer nanoparticles for overcoming multidrug resistance Biomacromolecules 14 2013 2636 2646
113. X.Y. Zhao, Y.J. Zhu, F. Chen, B.Q. Lu, C. Qi, J. Zhao, and J. Wu Calcium phosphate hybrid nanoparticles: self-assembly formation, characterization, and application as an anticancer drug nanocarrier Chem. Asian J. 8 2013 1306 1312
114. C. Zheng, M. Zheng, P. Gong, J. Deng, H. Yi, P. Zhang, Y. Zhang, P. Liu, Y. Ma, and L. Cai Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy Biomaterials 34 2013 3431 3438
115. Y. Zhou, J. Yang, J.S. Rhim, and J. Kopecek HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects J. Control. Release: Off. J. Control. Rel. Soc. 172 2013 946 953